ArticleCureus2026
Dupilumab-Associated Severe Headaches in Chronic Rhinosinusitis With Nasal Polyposis (CRSwNP): A Report of Two Cases With Resolution After Cessation.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Dupilumab is a monoclonal antibody that targets interleukin (IL)-4 and IL-13, approved for the treatment of chronic rhinosinusitis with nasal polyposis (CRSwNP). While common adverse effects such as conjunctivitis and injection-site reactions are well characterized, headaches reported in clinical trials are typically described as mild, non-specific, and rarely treatment-limiting. We describe two patients with CRSwNP who developed severe, recurrent headaches shortly after initiating dupilumab therapy. In one case, symptoms improved after discontinuation and recurred upon rechallenge; in the other, the headaches resolved after discontinuation. These observations raise the possibility that dupilumab-associated headaches may occasionally be more severe than previously appreciated. Clinicians should be aware of this potential association when evaluating new-onset headaches in patients receiving dupilumab.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.